Kidney Failure, Chronic Clinical Trial
Official title:
Effect of a High Protein and Low Glycemic Index Diet on Kidney Transplant
This study is a randomized clinical trial, which will follow and evaluate 120 kidney transplant recipients over one year. There will be two groups: a control group and the intervention group. The dietitian visits will happen monthly during the first six months and twice in the last six months.The intervention group will receive a high-protein and low glycemic index diet (1,3g/kg/day of protein) and the control group will keep following the hospital standard protocol. The study assessments (weight, anthropometry and biochemistry) will be performed during these visits over one year after the randomization period.
Kidney transplantation is the greater renal replacement therapy and, compared with
dialysis,is associated with better quality of life and reduced costs over time. However, it
is well known that significant weight gain and obesity are very common after kidney
transplantation, mainly during the first year after transplant. Besides, obesity is a risk
factor for the development of cardiovascular complications, new-onset diabetes after
transplantation and it is associated with graft loss. The use of immunosuppressive
medications, the break of dietary restrictions associated with dialysis period and
improvements in appetite are acceptable causes for weight gain. However, there is a lack of
evidence for effective nutritional interventions to prevent weight gain after kidney
transplant.
In this context, it is well known that high-protein and low glycemic index diets are
effective for body weight loss and subsequent weight maintenance. Moreover, protein
generally exerts a better satiety effect than carbohydrates and lipids. So that, considering
that there is a need to develop effective interventions to minimize the negative impact of
weight gain and obesity on kidney transplant outcomes, a randomized clinical trial, that
evaluate the effect of a high protein and low glycemic index diet (as a nutritional
intervention) is likely to be effective in preventing weight gain after kidney
transplantation.
This study is a randomized clinical trial, which will follow and evaluate kidney transplant
recipients during one year after transplantation. There will be two groups: a control group
(60 patients) and the intervention group (60 patients). The dietitian visits will happen
monthly at the first six months and twice in the last six months. The study assessments
(weight, anthropometry, body composition and biochemistry) will be performed during these
visits. Potential participants will be identified during their initial two months following
transplantation. Eligible transplant recipients will be invited to participate, given
detailed information about the trial and, if agreeable, will be asked to provide written
informed consent. Participants will be randomized to receive either nutrition intervention
with a high-protein and low glycemic index diet or an standard nutrition protocol. This
randomization will be performed by a statistical consultant using randomization.com site.
The length of the study will be 1 year for each patient, so that the assessment of
anthropometry, including measures of weight (monthly) and body composition (every three
months) will be performed by one specialist renal dietitian. Laboratory staff will perform
all laboratories testing, including serum and urine creatinine (monthly), glycemia,
cholesterol, HDL-cholesterol, triglycerides, glycated hemoglobin and uric acid (each three
months), high-sensitivity C- reactive protein (baseline and 6th month) and 24-h urine test
with albumin, protein, creatinine and urea excretion (every three months for intervention
group and at baseline, 3rd, 6th and 12th month for control group). Demographic and clinical
data will be assessed at the first dietitian visit. Body weight and height of patients will
be obtained and body mass index (BMI) (kg/m2) will be calculated. Waist circumference will
be measured midway between the lowest rib margin and the iliac crest, with flexible,
nonstretched fiberglass tape. This evaluation will be made every visit (monthly in the first
6 months and twice in the last 6 months). Body fat percentage (assessed each three months)
will be measured by using tetrapolar bioimpedance and basal metabolic rate will be evaluated
by indirect calorimetry at baseline and 6 months later. All the anthropometric assessment
will be performed with the patient fasting, wearing light clothing, without contact with
metals and without shoes. The prescription of the diet will be calculated by using
nutritional table by software version. It will be considered 1,3g /kg/day of protein and the
glycemic index will be estimated with glucose as standard food. Energy intake will be
assessed by a 24-h recall on the day of each dietitian visit by the research dietitian. Diet
composition also will be analyzed by using nutritional table by software and will be made in
every visit. Satiety levels will be assessed each three months for intervention group and
only at baseline for control group by using a visual analogue scale of appetite.
;
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
Completed |
NCT02922361 -
Spending and Outcomes for Complex Medicare Advantage Patients
|
||
Completed |
NCT02235571 -
iChoose Decision Kidney Aid for End-Stage Renal Disease Patients
|
N/A | |
Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
Completed |
NCT01922843 -
A Phase 2 Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism in Patients on Hemodialysis
|
Phase 2 | |
Completed |
NCT01930396 -
Use of Tinzaparin for Anticoagulation in Hemodialysis
|
Phase 4 | |
Not yet recruiting |
NCT01674660 -
Factors Associated With Interdialytic Blood Pressure Variability in Maintenance Hemodialysis Patients
|
N/A | |
Completed |
NCT01209403 -
Insulin-like Growth Factor (IGF-I) in Hemodialysis Patients
|
Phase 4 | |
Not yet recruiting |
NCT01157260 -
The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00753116 -
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
|
Phase 1 | |
Recruiting |
NCT00532688 -
N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure
|
Phase 2/Phase 3 | |
Completed |
NCT00534144 -
Comparison Between Effects of Two Iron Preparations on Protein in the Urine
|
Phase 1 | |
Completed |
NCT00528788 -
How Vitamin D Analogues Affect Endothelial Cells in Patients on Dialysis
|
Phase 4 | |
Completed |
NCT00382044 -
Audit of the Effect of Changing From IV to SC Administration of ESA's in Haemodialysis Patients
|
N/A | |
Completed |
NCT00226902 -
Vascular Reactivity in Kidney Disease Patients
|
N/A | |
Recruiting |
NCT00235287 -
Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT00224081 -
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
|
Phase 4 | |
Completed |
NCT00071214 -
Study to Evaluate the Effectiveness of StaphVAX in Adults on Hemodialysis
|
Phase 3 | |
Completed |
NCT00049907 -
Cardiac and Renal Disease Study (CARDS)
|
N/A | |
Completed |
NCT00006297 -
Risk Factors for CV Disease in a Dialysis Cohort
|
N/A |